Claims
- 1. 17β-allyloxy(thio)alkyl-androstane compounds having the general formula I whereinR1 is (H,OR), (H,OSO3H) or NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alkyl; n is 0, 1 or2; X is O, S, S(O) or S(O)2; each of R4 and R5 is independently hydrogen or (C1-4)alkyl; each of R6, R7 and R8 is independently hydrogen, phenyl, halogen or (C1-4)alkyl, optionally substituted by hydroxy, (C1-4)alkoxy or halogen; or R7 and R8 together with the carbon atom to which they are bound form a (C3-6)cycloalkane ring; or R6 and R7 together with the carbon atoms to which they are bound form a (C5-6)cycloalkene ring; and wherein the dotted lines indicate a Δ7 or a Δ8 double bond, or a pair of conjugated double bonds selected from Δ7,14, Δ8,14 and Δ6,8(14); or a pharmaceutically acceptable salt thereof.
- 2. A 17β-allyloxyalkyl-androstane compound according to claim 1, wherein n is 0 and X is O.
- 3. A 17β-allyloxyalkyl-androstane compounds of claim 2, wherein R1 is (H,OR), wherein R is H or (C1-6)acyl, the dotted lines indicate a pair of conjugated double bonds selected from Δ7,14, Δ8,14 and Δ6,8(14), and the configuration of the 3-OR substituent is the β-configuration.
- 4. A 17β-allyloxyalkyl-androstane compounds selected from the group consisting of (3β,5α,20R)-4,4-dimethyl-22-oxacholesta-8,14,24-trien-3-ol and (3β,5α,20S)-4,4-dimethyl-23-oxacholesta-8,14,25-trien-3-ol.
- 5. A pharmaceutical composition comprising a 17β-allyloxy(thio)alkyl-androstane having the general formula I, of claim 1 or a pharmaceutically acceptable salt thereof, in admixture with pharmaceutically acceptable auxiliaries.
- 6. A method of controlling fertility in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1.
- 7. A process for preparing a pharmaceutical composition, comprising mixing together a compound of claim 1 with pharmaceutically acceptable auxiliaries.
Priority Claims (1)
Number |
Date |
Country |
Kind |
97201691 |
Jun 1997 |
EP |
|
Parent Case Info
This application is a 371 of PCT/EP98/03191 filed on May 28, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP98/03191 |
|
WO |
00 |
12/3/2000 |
12/3/2000 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/55498 |
12/10/1998 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5716777 |
Byskov et al. |
Feb 1998 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 96 00235 |
Jan 1996 |
WO |
WO 96 27658 |
Sep 1996 |
WO |
WO 9700884 |
Jan 1997 |
WO |
Non-Patent Literature Citations (2)
Entry |
Byskov et al., Nature, 374(6522):559-562 (1995). |
Dygos et al., J. Org. Chem., 44(10):1590-1596 (1979). |